Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H28N2O3.C4H4O4 |
| Molecular Weight | 508.5629 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C3=CC=C(O)C4=C3C=CC(=O)N4
InChI
InChIKey=IREJFXIHXRZFER-PCBAQXHCSA-N
InChI=1S/C24H28N2O3.C4H4O4/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24;5-3(6)1-2-4(7)8/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29);1-2H,(H,5,6)(H,7,8)/b;2-1-/t22-;/m0./s1
Indacaterol is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It was approved by the European Medicines Agency (EMA) under the trade name Onbrez Breezhaler on November 30, 2009, and by the United States Food and Drug Administration (FDA), under the trade name Arcapta Neohaler, on July 1, 2011. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered as an aerosol formulation through a dry powder inhaler.
CNS Activity
Originator
Approval Year
PMID
| Title | Date | PMID |
|---|---|---|
| Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. | 2005 Jul |
|
| Gateways to clinical trials. | 2006 Dec |
|
| Gateways to clinical trials. | 2006 Jan-Feb |
|
| In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. | 2006 May |
|
| Indacaterol Novartis/skyePharma. | 2006 May |
|
| Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. | 2007 |
|
| ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD? | 2007 |
|
| Gateways to clinical trials. | 2007 Dec |
|
| Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma. | 2007 Dec |
|
| Gateways to clinical trials. | 2007 Jan-Feb |
|
| Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi. | 2007 Mar |
|
| Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma. | 2007 May |
|
| Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study. | 2007 Oct |
|
| New approaches to managing asthma: a US perspective. | 2008 Apr |
|
| Efficacy and safety of indacaterol, a new 24-hour beta2-agonist, in patients with asthma: a dose-ranging study. | 2008 Dec |
|
| Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study. | 2008 Jan |
|
| Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. | 2008 Jan |
|
| A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. | 2008 Jul |
|
| Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthma. | 2008 Jul |
|
| Gateways to clinical trials. | 2008 May |
|
| A cell-based assay to assess the persistence of action of agonists acting at recombinant human beta(2) adrenoceptors. | 2008 Nov-Dec |
|
| Gateways to clinical trials. | 2008 Oct |
|
| Novel long-acting bronchodilators for COPD and asthma. | 2008 Oct |
|
| Gateways to clinical trials. | 2009 Apr |
|
| Effect of pre-contraction on β-adrenoceptor-mediated relaxation of rat urinary bladder. | 2009 Dec |
|
| Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties? | 2009 Dec 8 |
|
| 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol. | 2009 Feb |
|
| Gateways to clinical trials. | 2009 Jan-Feb |
|
| Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases. | 2009 Jul |
|
| Indacaterol, A Novel Once Daily Inhaled beta2-Adrenoreceptor Agonist. | 2009 Mar 12 |
|
| Mometasone furoate: an effective anti-inflammatory with a well-defined safety and tolerability profile in the treatment of asthma. | 2009 May |
|
| 24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma: comparison with placebo and formoterol. | 2009 Oct |
|
| Gateways to clinical trials. | 2009 Sep |
|
| The long-acting beta-adrenoceptor agonist, indacaterol, inhibits IgE-dependent responses of human lung mast cells. | 2009 Sep |
|
| Pharmacogenetic characterization of indacaterol, a novel beta 2-adrenoceptor agonist. | 2009 Sep |
|
| [Efficacy and safety of indacaterol - new long-acting beta(2) agonist]. | 2010 |
|
| Impact of bronchodilator therapy on exercise tolerance in COPD. | 2010 Apr 7 |
|
| QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. | 2010 Dec |
|
| Indacaterol once-daily is equally effective dosed in the evening or morning in COPD. | 2010 Dec |
|
| Novel bronchodilators in asthma. | 2010 Jan |
|
| Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. | 2010 Jul 15 |
|
| Indacaterol: a new once daily long-acting beta(2) adrenoceptor agonist. | 2010 Jun 15 |
|
| The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease. | 2010 Mar |
|
| Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. | 2010 Mar 8 |
|
| 24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: a comparison with placebo and salmeterol. | 2010 Nov |
|
| Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. | 2010 Oct 29 |
|
| Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. | 2010 Oct 5 |
|
| Bronchodilator efficacy of single doses of indacaterol in Japanese patients with COPD: A randomised, double-blind, placebo-controlled trial. | 2010 Sep |
|
| Efficacy is a contributing factor to the clinical onset of bronchodilation of inhaled beta(2)-adrenoceptor agonists. | 2010 Sep |
|
| Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study. | 2017 Jan 11 |
Sample Use Guides
The recommended dosage of Indacaterol is the once-daily inhalation of the contents of one 75 mcg Indacaterol capsule using the NEOHALER inhaler.
Route of Administration:
Respiratory
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
OSLIF BREEZHALER (AUTHORIZED: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by
admin on Tue Mar 06 11:15:37 UTC 2018 , Edited by admin on Tue Mar 06 11:15:37 UTC 2018
|
||
|
EMA ASSESSMENT REPORTS |
HIROBRIZ BREEZHALER (AUTHORIZED: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by
admin on Tue Mar 06 11:15:37 UTC 2018 , Edited by admin on Tue Mar 06 11:15:37 UTC 2018
|
||
|
EMA ASSESSMENT REPORTS |
ULUNAR BREEZHALER (AUTHORIZED: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by
admin on Tue Mar 06 11:15:37 UTC 2018 , Edited by admin on Tue Mar 06 11:15:37 UTC 2018
|
||
|
EMA ASSESSMENT REPORTS |
ONBREZ BREEZHALER (AUTHORIZED: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by
admin on Tue Mar 06 11:15:37 UTC 2018 , Edited by admin on Tue Mar 06 11:15:37 UTC 2018
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1114325
Created by
admin on Tue Mar 06 11:15:37 UTC 2018 , Edited by admin on Tue Mar 06 11:15:37 UTC 2018
|
PRIMARY | RxNorm | ||
|
9827599
Created by
admin on Tue Mar 06 11:15:37 UTC 2018 , Edited by admin on Tue Mar 06 11:15:37 UTC 2018
|
PRIMARY | SWITZERF | ||
|
753498-25-8
Created by
admin on Tue Mar 06 11:15:37 UTC 2018 , Edited by admin on Tue Mar 06 11:15:37 UTC 2018
|
PRIMARY | |||
|
M6240
Created by
admin on Tue Mar 06 11:15:37 UTC 2018 , Edited by admin on Tue Mar 06 11:15:37 UTC 2018
|
PRIMARY | Merck Index | ||
|
CHEMBL1095777
Created by
admin on Tue Mar 06 11:15:37 UTC 2018 , Edited by admin on Tue Mar 06 11:15:37 UTC 2018
|
PRIMARY | |||
|
SUB30300
Created by
admin on Tue Mar 06 11:15:37 UTC 2018 , Edited by admin on Tue Mar 06 11:15:37 UTC 2018
|
PRIMARY | |||
|
C81640
Created by
admin on Tue Mar 06 11:15:37 UTC 2018 , Edited by admin on Tue Mar 06 11:15:37 UTC 2018
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
